<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Furfaro AL</submitter><funding>Italian Ministry of Health</funding><funding>British Heart Foundation</funding><funding>COST Action BenBedPhar</funding><funding>Heart Research UK</funding><funding>COST action</funding><pagination>1171</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9219655</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(6)</volume><pubmed_abstract>Induction of heme oxygenase 1 (HO-1) favors immune-escape in BRAF&lt;sup>V600&lt;/sup> melanoma cells treated with Vemurafenib/PLX4032 under standard cell culture conditions. However, the oxygen tension under standard culture conditions (~18 kPa O&lt;sub>2&lt;/sub>) is significantly higher than the physiological oxygen levels encountered in vivo. In addition, cancer cells in vivo are often modified by hypoxia. In this study, MeOV-1 primary melanoma cells bearing the BRAF&lt;sup>V600E&lt;/sup> mutation, were adapted to either 5 kPa O&lt;sub>2&lt;/sub> (physiological normoxia) or 1 kPa O&lt;sub>2&lt;/sub> (hypoxia) and then exposed to 10 μM PLX4032. PLX4032 abolished ERK phosphorylation, reduced Bach1 expression and increased HO-1 levels independent of pericellular O&lt;sub>2&lt;/sub> tension. Moreover, cell viability was sign</pubmed_abstract><journal>Antioxidants (Basel, Switzerland)</journal><pubmed_title>HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF&lt;sup>V600E&lt;/sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.</pubmed_title><pmcid>PMC9219655</pmcid><funding_grant_id>BenBedPhar CA20121</funding_grant_id><funding_grant_id>FS/16/67/32548</funding_grant_id><funding_grant_id>CA20121</funding_grant_id><funding_grant_id>RG2673</funding_grant_id><funding_grant_id>RF-2016-02362288</funding_grant_id><pubmed_authors>Nitti M</pubmed_authors><pubmed_authors>Pietra G</pubmed_authors><pubmed_authors>Passalacqua M</pubmed_authors><pubmed_authors>Ivaldo C</pubmed_authors><pubmed_authors>Furfaro AL</pubmed_authors><pubmed_authors>Mann GE</pubmed_authors><pubmed_authors>Loi G</pubmed_authors></additional><is_claimable>false</is_claimable><name>HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF&lt;sup>V600E&lt;/sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.</name><description>Induction of heme oxygenase 1 (HO-1) favors immune-escape in BRAF&lt;sup>V600&lt;/sup> melanoma cells treated with Vemurafenib/PLX4032 under standard cell culture conditions. However, the oxygen tension under standard culture conditions (~18 kPa O&lt;sub>2&lt;/sub>) is significantly higher than the physiological oxygen levels encountered in vivo. In addition, cancer cells in vivo are often modified by hypoxia. In this study, MeOV-1 primary melanoma cells bearing the BRAF&lt;sup>V600E&lt;/sup> mutation, were adapted to either 5 kPa O&lt;sub>2&lt;/sub> (physiological normoxia) or 1 kPa O&lt;sub>2&lt;/sub> (hypoxia) and then exposed to 10 μM PLX4032. PLX4032 abolished ERK phosphorylation, reduced Bach1 expression and increased HO-1 levels independent of pericellular O&lt;sub>2&lt;/sub> tension. Moreover, cell viability was sign</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-19T11:13:18.375Z</modification><creation>2025-02-19T02:15:37.228Z</creation></dates><accession>S-EPMC9219655</accession><cross_references><pubmed>35740068</pubmed><doi>10.3390/antiox11061171</doi></cross_references></HashMap>